Third Harmonic Bio, Inc. (THRD)
| Previous Close | 11.59 |
| Open | 11.51 |
| Bid | 11.60 x 100 |
| Ask | 12.10 x 100 |
| Day's Range | 11.59 - 11.59 |
| 52 Week Range | 4.31 - 12.42 |
| Volume | |
| Avg. Volume | 151,677 |
| Market Cap | 472.371M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.55 |
GuruFocus.comThird Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares
Natalie Holles, CEO of Third Harmonic Bio Inc (NASDAQ:THRD), has sold 13,558 shares of the company on April 11, 2024, according to a recent SEC Filing.
Simply Wall St.We're Not Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. “Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, i
